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ABSTRACT 
The purpose of this study was to develop and optimize microemulsion containing agomelatine for intranasal delivery. Agomelatine, an 
antidepressant drug, has absolute bioavailability of only 5% due to high first pass metabolism. Agomelatine microemulsion and were prepared 
by titration method. Ternary phase diagram gave the microemulsion region and the concentration of oil; Smix and water were selected from 
ternary phase diagram. Based on solubility study, oleic acid, tween 80 and propylene glycol were selected as oil, surfactant and co surfactant 
respectively. Microemulsions were prepared using water titration method. 1:1% v/v ratio (Tween 80: Propylene glycol) was selected for 
formulation development. The prepared microemulsions were optimized optical transparency, viscosity measurement, phase separation, 
determination of pH, measurement of globule size, measurement of zeta potential, drug content, In vitro diffusion study, stability studies. The 
optimized batch was further characterized for optical transparency, viscosity measurement, phase separation, determination of pH, 
measurement of globule size, measurement of zeta potential, drug content, In vitro diffusion study, stability studies.  
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INTRODUCTION 
Depression as estimated by WHO, depression shall become 
the second biggest illness in terms of morbidity by another 
decade in the world, already one out of every twelve men and 
five women have depression. With newer medication, and 
better facilities, treating depression has become easier, and 
most people respond very well to treatment, and return to 
optimum functioning very soon. Depression is a significant 
contributor to the global burden of disease and affects 
people in all communities across the world. Today, 
depression is estimated to affect 350 million people. The 
World Mental Health Survey conducted in 17 countries found 
that on average about 1 in 20 people reported having an 
episode of depression in the previous year. Depressive 
disorders often start at a young age; they reduce people’s 
functioning and often are recurring. For these reasons, 
depression is the leading cause of disability worldwide in 
terms of total years lost due to disability. The demand for 
curbing depression and other mental health conditions is on 
the rise globally. Depression is a common mental disorder 
that presents with depressed mood, loss of interest or 
pleasure, feelings of guilt or low self-worth, disturbed sleep 
or appetite, low energy, and poor concentration. Depression 
usually starts between the ages of 15 and 30, and is much 
more common in women. 1.  
The word microemulsion was originally proposed by 
Schulman et al. (1959). They prepared a quaternary solution 
of water, benzene, hexanol, and k-oleate which was stable, 
homogenous and slightly opalescent.. Basically a coarse (or 
macro) emulsion was prepared and the system was then 
titrated to clarify by adding a co-surfactant (second surface 
active substance). When the combination of the four 
components was right, the system cleared spontaneously. 
Most of the work reported by Schulman dealt with four 
component systems. Hydrocarbons (aliphatic or aromatic), 
ionic surfactants, co surfactants (generally 4–8 carbon chain 
aliphatic alcohol) and an aqueous phase. Schulman had 
previously published extensively in the field of monolayers 
and applied what he had learnt in that field to explain the 
formation of microemulsions. The surfactant and co-
surfactant, when properly selected, form a mixed film at the 
oil/water interface, resulting in an interfacial pressure 
exceeding the initial positive interfacial tension.2, 3 
Microemulsions are thermodynamically stable isotropic 
systems in which two immiscible liquids (water and oil) are 
mixed to form a single phase by means of an appropriate 
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surfactant or its mixture. The short to medium chain alcohols 
are generally considered as co surfactants in the 
microemulsion system. The presence of surfactant and co 
surfactant in the system makes the interfacial tension very 
low. Therefore microemulsions form spontaneously, with an 
average droplet diameter of 10 to 140 nm. Microemulsions 
offer several advantages like high solubilization of lipophilic 
drugs, stability, ease of preparation and stabilization of 
hydrolytically susceptible compounds. Microemulsions 
provide a large surface area for better absorption of drugs 
due to smaller globule size. Various drugs such as 
Sumatriptan, Zolmitriptan, Cabergoline, Clonazepam, 
Nimodipine, Tacrine, and Diazepam have been successfully 
delivered through nasal route in the form of microemulsion 
and it resulted in improved drug absorption. In order to 
formulate a nasal formulation with desirable performance, it 
is advisable to focus on maximizing the residence time in the 
nasal mucosa and thus ensuring efficient absorption of drug. 
Use of mucoadhesive polymers in the nasal formulations is 
expected to increase the residence time and thereby enhance 
the absorption of the drug. 3-12 
MATERIALS AND METHODS 
Agomelatine was obtained as a gift sample from Enaltec 
Labs, Igatpuri, Nashik, India. Tween 80 and propylene glycol 
were purchased from Research-Lab Fine Chem. Industry –
Mumbai. 
Construction of pseudo ternary phase diagram- 
Pseudo-ternary phase diagrams were constructed using 
water titration method at ambient temperature (25°) to 
determine the ME regions. Pseudo ternary phase diagram 
was plotted for each Smix 1:1, 1:2 and 2:1 using the CHEMIX 
Software (Version 7.00). 13 
Formulation of Microemulsion- 
Based on the phase diagram, the optimum Smix ratio was 
selected and the drug loaded microemulsiom were prepared 
by dissolving the drug in the oil-Smix mixture, and then 
titrated with water on the magnetic stirrer at 150 RPM for 
10 min. Agomelatine was added to the specific amount oil 
then surfactant and co-surfactant with varying percentage, 
and then an appropriate amount of water was added to the 
mixture drop by drop with constant stirring on magnetic 
stirrer. Microemulsions containing agomelatine were 
obtained spontaneously on stirring the mixtures. All 
microemulsions were stored at appropriate temperature. 
Four formulations containing different concentration of oil, 
Surfactant/co-surfactant were prepared with the help of 
selected region area of pseudo ternary phase diagram. Each 
formulation was prepared according to the procedure 
explained above and then these formulations were 
evaluated. 14, 15 
Evaluation of Microemulsion-  
The Microemulsion was evaluated for the following 
characteristics: 7, 8, 9, 14, 15, 16 
a. Optical Transparency-  
Optical transparency of the formulation was determined by 
inspecting the sample in clear and transparent container 
under the presence of light against reflection into the eyes.  
 b. Viscosity Measurement-   
The Viscosities of microemulsions were measured using a 
Brookfield rotational viscometer (LV2, Brookfield Inc., USA) 
at 24.9˚ at 10 rpm.  
 
c. Phase Separation-  
Microemulsion system were subjected to centrifugation 
(Remi Motor, Mumbai) at 3000 rpm for a period of 2 h and 
examined for any evidence of phase separation. 
d. Determination of pH 
A 10% dispersion of formulation was prepared in distilled 
water and pH was determined by using pH meter which was 
prior standardized with standard buffers of pH 4 and pH 7. 
e. Measurement of Globule Size  
The average globule size of the microemulsions was 
determined by Zetasizer Nano-ZS (Malvern Instruments, 
UK). Measurements were carried at an angle of 90◦ at 25◦. 
Microemulsion was diluted with double distilled water to 
ensure that the light scattering intensity was within the 
instrument’s sensitivity range. All the measurement was 
carried out at 25˚. The polydispersity index of the 
formulation was determined by the same instrument. The 
width of the size distribution was indicated by the 
polydispersity index (P.I) 
f. Measurement of zeta potential- 
The zeta potential was determined to verify stability of 
microemulsion due to charge interaction. Zeta potential was 
measured by using Zetasizer Nano-ZS (Malvern Instruments, 
UK).  The measurement was performed at 25°.   
g. Drug Content- 
A definite volume of formulation was taken in a 10 ml 
volumetric flask and diluted with methanol. The resultant 
solution was sonicated for 3 min at ambient temperature and 
the absorbance of the resultant solution was measured at 
λmax of 234 nm against blank. 
h. In vitro diffusion study- 
In vitro diffusion was carried out by modified franz diffusion 
cell. A glass cylinder with both ends open, 10 cm height, 3.7 
cm outer diameter and 3.1 cm inner diameter was used as 
diffusion cell. A sheep nasal mucosa was fixed to one end of 
the cylinder with the aid of an to result as a diffusion cell. 1 
ml of microemulsion was taken in the cell (donor 
compartment) and cell was immersed in a beaker containing 
100 ml of pH 6.4 Phosphate buffer as receptor compartment. 
The entire surface of the cell was in contact with the receptor 
compartment which was agitated using magnetic stirrer and 
a temperature of 37±1° was maintained. Samples 10 ml of 
the receptor compartment were taken and with same 
amount replaced to maintain sink condition. The sample was 
analyzed for agomelatine at 234 nm against blank using UV 
Spectrophotometer. Amount of agomelatine released at 
various time intervals was calculated with the help of 
calibration curve with phosphate buffer and plotted against 
time.   
i. Stability Studies-  
The microemulsions were subjected to stability study at 40º 
C± 20 C, 75 % RH±5% RH for 6 mo. The samples were 
evaluated for transparency, drug contents, pH, and in vitro 
drug release for 6 mo period.   
RESULT AND DISCUSSION 
Pseudo Ternary Phase Diagram- 
Plotting of pseudo ternary phase diagram for formulation of 
microemulsion with Smix ratio (1:1, 1:2, 2:1). Pseudo ternary 
phase diagram shown in following fig. 1 respectively. 
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Percent composition of selected ratio of microemulsion 
formulation-  
Pseudo ternary phase diagram of ratio 1:1 gave the clear 
transparent microemulsion as compare to 1:1 and 2:1 ratio. 
So 1:1 ratio was selected for further final preparation as 
shown in Table 1 & figure 2. 
 
 
 
 
 
 
Figure 1: Pseudo ternary phase diagram 
 
Table 1: Composition of microemulsion 
Ingredients ME1 ME2 ME3 
Agomelatine 1.25 1.25 1.25 
Oleic Acid 5 14 10 
Tween 80 37.5 33 35 
Propylene Glycol 37.5 33 35 
Water 20 20 20 
a. 
b. 
c. 
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Figure 2: Pseudo ternary phase diagram of ratio 1:1 
 
Evaluation of Microemulsion-  
Evaluation of Microemulsion- 
a. Optical Transparency-  
Optical transparency of the formulation was determined by 
inspecting the sample in clear and transparent container 
(glass beaker) under the presence of light against reflection 
into the eyes. All the formulations observed clear and 
transparent formulation microemulsion shown in Table 2 
and fig. 3. 
Table 2: Optical Transparency 
Formulation Transparency 
ME1 Transparent 
ME2 Transparent 
ME3 Transparent 
 
 
 
Figure 3: Optical Transparency of all Three 
Formulations 
 
b. Viscosity Measurements- 
The Viscosities of all the formulations Microemulsions were 
measured using a Brookfield rotational viscometer (LV2, 
Brookfield Inc., USA) at 24.9˚ at 10 rpm. Formulation with 
higher viscosity has a better contact time thus increases the 
absorption. At the same time, high viscosity enhanced the 
permeability of drug and shown in Table 3. 
 
Table 3: Viscosity Measurement 
Formulations Viscosity (cps) (±SD) 
ME1 245.9 ± 0.81 
ME2 236.9 ± 0.86 
ME3 248.3 ± 0.67 
 
c. Phase Separation-   
Microemulsion system were subjected to centrifugation 
(Remi Motor, Mumbai) at 3000 rpm for a period of 2 h and 
examined for any evidence of phase separation and shown in 
Table 4. 
d. Determination of pH-   
pH of various microemulsion are shown in the following 
table no. 17 which was found to be in range of 4.93 to 5.10. 
Nasal irritation is minimized when products are delivered 
with a pH range of 4.5 to 6.5 and shown in Table 5. 
e. Measurement of Globule Size-   
The globule size of the microemulsion formulation of 
optimized batch was found to be 122.0 nm. The 
polydispersity index of formulation was determined by 
zetasizer. The width of the size distribution was indicated by 
polydiserpersity index, which shown in fig. 4 and Table 6. 
Table 4: Phase Separation 
Formulations Phase Separation 
ME1 No Phase Separation 
ME2 No Phase Separation 
ME3 No Phase Separation 
 
Table 5: Determination of pH 
Formulations pH (±SD) 
ME1 4.93 ± 0.91 
ME2 5.02  ± 0.45 
ME3 5.10 ± 0.46 
 
Table 6: Globule Size Analysis 
Formulations Globule Size ( nm) PDI 
ME1 291.8 0.571 
ME2 195.7 0.463 
ME3 122.0 0.203 
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f. Measurement of Zeta Potential- 
It should be negative or neutral. Which indicate that droplets 
of micro emulsion having no charge, that is system is stable. 
It is determined by using Zetasizer. Zeta potential is 
essentially useful for assessing flocculation since electrical 
charges on particles influence the rate of flocculation. To 
retain the stability of microemulsions it should be zero or 
neutral. The zeta potential was determined to verify stability 
of microemulsion due to charge interaction. Zeta potential 
was measured by using Zetasizer Nano-ZS (Malvern 
Instruments, UK).  The measurement was performed at 25° 
which shown in fig. 4 and Table 7. 
Table 7: Measurement of Zeta Potential 
Formulations Zeta Potential 
ME1 -14.1 
ME2 -30.0 
ME3 -32.9 
 
 
 
 
 
 
Figure 4: Representation of the obtained data for Zeta potential of microemulsion 
(a) ME1; (b) ME2; (c) ME3 
a. 
b. 
c
. 
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g. Drug Contents-  
The percentage drug content of all prepared microemulsion formulations was found to be in the range of 81.65 to 88.85 %. The 
ME3 Formulation drug content was found to be 88.85% and shown in Table 8. 
h. In vitro diffusion study- 
Out of the 3 formulations maximum release after 1 ho was found for ME3 formulation. This indicates release of 83.09% drug 
availability, shown in fig. 5 and Table 9. 
Table 8: Drug Content 
Formulations Drug Content % (±SD) 
ME1 85.45 ± 0.56 
ME2 81.65 ± 0.62 
ME3 88.85 ± 0.75 
 
Table 9: In-Vitro Diffusion Study 
Time in min. ME1 ME2 ME3 
5 15.25 ± 0.54 13.52 ± 60 11.78 ± 0.64 
10 19.66 ± 0.78 19.47 ± 0.60 20.54 ±  0.62 
15 25.45 ± 0.66 24.63 ± 0.64 28.12 ± 0.57 
20 29.02 ± 0.55 30.84 ± 0.67 35.75 ± 0.65 
25 36.85 ± 0.65 36.63 ± 0.64 41.95 ± 0.74 
30 40.65 ± 0.63 42.14 ± 0.60 49.35 ± 0.67 
35 47.12 ± 0.55 49.82 ± 0.67 54.15 ± 0.56 
40 52.88 ± 0.67 54.37 ± 0.59 60.52 ± 0.62 
45 57.78 ± 0.65 60.46 ± 0.41 66.74 ± 0.64 
50 64.61 ± 0.59 65.91 ± 0.69 71.03 ±  0.51 
55 71.43 ± 0.61 71.73 ± 0.44 78.13 ± 0.59 
60 78.46 ± 0.58 76.12 ± 0.52 83.09 ± 0.54 
 
 
  
 
Figure 5: In Vitro diffusion Study  (a) In Vitro diffusion Study assembly; (b) In Vitro drug release 
i. Stability Studies-  
The microemulsions were subjected to stability study at 40º ± 20 C, 75 % RH±5% RH for 6 mo respectively. The samples were 
evaluated for transparency, drug contents, pH, and in vitro drug release every month for 6 mo period and shown in Table 10.  
Table 10: Stability Studies 
Sr. No. Observation Before Accelerated 
Stability Testing 
After Accelerated Stability Testing 
 180 days  
1. Visual appearance (Transparency) Transparent  Transparent  
2. Drug content (%) (± SD) 88.85 ± 0.75  86.95 ± 0.50  
3. pH (±SD) 5.10 ± 0.46  5.20 ± 0.52  
4. In vitro drug release (±SD) 83.09 ± 0.54  81.01 ± 0.46  
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Formulation ME 3 was found to be transparent and stable up 
to 6 mo have there is no significant change in drug content, 
visual appearance.  
Finally, it can be summarized that the microemulsion of 
agomelatine can be one of the promising tool in improve 
bioavailability, increases the rate of absorption due to the 
small globule size and by avoiding first pass metabolism and 
direct transport into systemic circulation for effective and 
longer treatment required for antidepressant action with 
increased stability. 
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